Biopharmaceutical company Korro Bio, Inc. (KRRO) announced a new collaboration with Danish healthcare firm Novo Nordisk A/S (NVO) on Monday. This partnership aims to further the discovery and development of genetic medicines, with a primary focus on treating cardiometabolic diseases.
This collaboration leverages Novo Nordisk's extensive understanding and experience in cardiometabolic disease and drug development, together with Korro's proprietary platform for developing RNA editing product candidates targeting two unspecified areas.
Per the agreement, Korro stands to receive up to $530 million in upfront payments, as well as development and commercial milestone payments. Additionally, the agreement includes tiered royalties and funding for research and development.
Korro will progress up to two programs through the preclinical development phase. After this stage, Novo Nordisk has the option to continue advancing these programs into clinical studies.
